It is demonstrated that Nrf2 is linked not only to the progression of RCC but also to resistance to chemotherapy; thus, the Nrf2/KEAP1 pathway could be a promising target for the treatment of RCC. Here, NFE2L2 is linked to renal cell carcinoma.